Hi Gumnut70 I could be wrong, but believe comment on the relative cohort performance will be kept until the final report in Q3, or perhaps this will have to be in Q4 now (even better). I suspect that most if not all of the ongoing patients are from cohort 3, and that they would like to have these results in before reporting on relative cohort performance.
Having said that, I believe there are only 2 options. Either the small number of run out patients in cohort 2 performed incredibly well, and I mean incredibly, or the Kaplan–Meier curve is predicting a median of around 22 months for cohort 3 patients.St Vincent's Hospital are playing this conservatively imo, because no one would like to make the announcement and then be proven wrong. Nevertheless, that prediction can be inferred. I believe that we Noxopharm shareholder's are in for very exciting times.
NOX Price at posting:
83.0¢ Sentiment: Hold Disclosure: Held
